Top 10 Emerging Technology Company in 2012

Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company")

Named as Top Emerging Technology Company in 2012

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reformulate medicines, has been featured in Lux Research's "Top Emerging Technology Companies in 2012". 

Lux Research profiled 1,380 companies across 15 different emerging technology domains in 2012 and to conclude the year, selected the 10 most compelling companies they had profiled in 2012 across all its coverage areas, with Oxford Pharmascience making the top 10.

Nigel Theobald, CEO, commented: 

"It is fantastic to be recognised in this way by such a respected research company as Lux.

We have invested in some exciting technologies for reformulating existing medicines and wholeheartedly agree that through our partnerships with major pharma companies we will indeed have some very compelling products to bring to market "

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

N+1 Singer

Shaun Dobson/ Aubrey Powell +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

Oxford Pharmascience develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.